Sai Parenterals Limited presented its investor update for the quarter ended June 30, 2026, on August 12, 2026, detailing a strategic shift towards regulated markets through a ₹571 crore capital expenditure programme. The company reported a consolidated net profit before tax of ₹11.9 crore for FY26, driven by the integration of Noumed Pharmaceuticals, which was consolidated with effect from November 12, 2025. Management emphasized that year-on-year comparisons are not like-for-like due to this recent acquisition, which adds significant revenue visibility through long-term contracts in Australia and New Zealand.

The Board has proposed a variation in the utilization of IPO proceeds under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The variation reallocates funds from capacity expansion of existing units to two new acquisitions: a 60% stake in Saicriti Pharma Private Limited for ₹83.83 crore and a 60% stake in Prathyak Laboratories Private Limited for ₹15.0 crore. These transactions aim to replace constrained injectable facilities within the Outer Ring Road (ORR) of Hyderabad with a new greenfield facility at Gummadidala and an operating R&D centre at Genome Valley. Shareholder approval is required for these changes.

Capital Expenditure and Facility Upgrades

The total capex programme stands at ₹571 crore, with the company’s own funded share remaining unchanged at ₹440 crore. The investment is distributed across four key projects:

Units I and II at Jeedimetla are scheduled for discontinuation upon commissioning of the new Saicriti facility. The Adelaide facility, supported by a AUD 20 million grant from the Australian Government, aims to shift production from outsourced distribution margins to higher manufacturing margins.

Operational Highlights and Market Position

Sai Parenterals operates across two verticals: Branded Generic Formulations and Contract Development and Manufacturing Organization (CDMO). Over 50% of consolidated revenue is contracted under long-term agreements in regulated markets. The private-sector revenue share rose from 39% in FY23 to 81% in FY26, indicating reduced reliance on tender-based sales. The company holds 599 approved registrations and has 67 dossiers under development, targeting patent expiries over the next three years.

Financial Performance Context

Consolidated cash generated from operations stood at ₹98.0 crore in FY26, compared to ₹33.7 crore in FY25. Net profit before tax was ₹11.9 crore in FY26 versus ₹19.9 crore in FY25. The decline in profitability despite higher operating cash flow reflects the initial integration costs and non-recurring items associated with the Noumed acquisition and ongoing capex investments. Cash and cash equivalents increased significantly to ₹417.0 crore at the end of FY26 from ₹2.1 crore in FY25, bolstered by financing activities totaling ₹595.7 crore.

What the Numbers Show

The financial data reveals a transitional phase where operational cash generation has improved substantially (₹98.0 crore in FY26 vs ₹33.7 crore in FY25), yet net profit before tax contracted (₹11.9 crore vs ₹19.9 crore). This divergence suggests that while core operations are generating stronger cash flows, the bottom line is currently impacted by integration expenses and the high capital intensity of the expansion programme. The substantial increase in cash reserves (₹417.0 crore) provides a buffer for the upcoming debt obligations linked to the Saicriti facility, which includes a ₹75.24 crore project debt component.

Sai Parenterals Limited has appointed new auditors for the financial year 2026-27 and authorized its Managing Director to explore strategic growth opportunities. The decisions were taken during a board meeting held on July 06, 2026, at the company's registered office. These appointments are subject to necessary regulatory approvals and shareholder consent where applicable.

Auditor Appointments

The board approved the appointment of M/s. Aakanksha Dubey & Co., Practicing Company Secretaries, as Secretarial Auditors for a period of five financial years, from 2026-27 to 2030-31. This appointment is subject to the approval of shareholders. For the financial year 2026-27, the board appointed M/s. NSVR & Associates LLP, Chartered Accountants, as Internal Auditors and M/s. Sai Krishna & Associates, Cost Accountants, as Cost Auditors.

Strategic Authorization

In addition to the auditor appointments, the board authorized Mr. Anil Kumar Karusala, Chairman & Managing Director, to identify, evaluate, and explore suitable organic and inorganic growth opportunities. This mandate covers the existing line of business as well as other strategic areas deemed beneficial to the company.

Appointment Details